Acta neurologica Scandinavica
-
Acta Neurol. Scand. · Nov 2017
ReviewThe clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy.
In natalizumab-treated patients without previous immunosuppressive treatment, the JCV antibody index is used to stratify PML risk. A high index value indicates that the risk to develop PML is significantly elevated, although probably about 99% of patients with this index value will not develop PML. This minireview aimed to provide an overview of the basic virology and immunology relevant to understanding JCV infections in MS patients, with a focus on what is presently known about antibodies to JCV and how they could be of use to predict and diagnose PML.